What Is Stanniocalcin? Definition and What Research Reports
Stanniocalcin is a secreted glycoprotein hormone, present in mammals as two related proteins, STC1 and STC2, that was first described in bony fish as a regulator of calcium and phosphate handling. In current research the term mostly appears in work on the stanniocalcin–PAPP-A–IGFBP–IGF signalling axis, on tissue injury and inflammation, and on tumour biology, where STC1 and STC2 expression has been studied in several cancer types. It is a signalling protein studied in laboratories, not a dosing protocol.
Definition
Stanniocalcin is a secreted, disulfide-linked glycoprotein hormone that exists in mammals as two homologues, stanniocalcin-1 (STC1) and stanniocalcin-2 (STC2). The name comes from the corpuscles of Stannius, endocrine structures in bony fish where the original protein was identified as a regulator of calcium and phosphate balance. Mammalian stanniocalcins are produced by many tissues rather than by a single gland, and they are generally described as acting locally, in autocrine or paracrine fashion, on nearby cells. A 2026 review in Endocrine Reviews framed stanniocalcin 1 as sitting at the intersection of calcium homeostasis, insulin-like growth factor (IGF) signalling and cancer immunity (PMID 42446003). This page is a reference definition only.
What Class of Molecule It Is
Stanniocalcin belongs to the class of secreted signalling glycoproteins — full-length, glycosylated proteins of roughly 250 amino acids in their mature form, not short synthetic sequences of the kind usually meant by the phrase "research peptide." That distinction matters when the term is encountered in peptide glossaries: STC1 and STC2 are endogenous proteins measured in tissue and blood, or manipulated in cells and animals by genetic methods, rather than compounds with established human dosing literature.
- STC1 — the closer homologue of the fish hormone; studied in kidney, gut, brain and tumour tissue.
- STC2 — a related gene product frequently examined in oncology datasets and in metabolic-stress biology.
- Family behaviour — both act as inhibitors of the protease PAPP-A, which places them upstream of IGF bioavailability, as described in a 2023 review of the stanniocalcin–PAPP-A–IGFBP–IGF axis (PMID 36718521).
How the Term Is Used in Research
In the published literature, "stanniocalcin" is used in three broad ways. First, as a component of a growth-factor axis: researchers described STC1 and STC2 as endogenous inhibitors of pregnancy-associated plasma protein-A (PAPP-A), the enzyme that cleaves IGF-binding proteins and thereby frees IGF-1 and IGF-2 for receptor binding, a relationship reviewed in detail in 2023 (PMID 36718521). Second, as a tissue-stress and injury marker, where expression rises in inflamed, fibrotic or metabolically stressed cells. Third, as a tumour biomarker or candidate driver, where expression levels are correlated with clinical or pathological features.
Because stanniocalcin is endogenous, most study designs are expression analyses, knockdown or overexpression experiments in cell lines, and animal models — not administration studies in people. Where this page describes an effect, it names the model the study used.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the Published Literature Reports
The stanniocalcin–PAPP-A–IGF axis
The 2023 Journal of Clinical Endocrinology and Metabolism review set out the stanniocalcin–PAPP-A–IGFBP–IGF axis as an integrated local control system for IGF activity, positioning the stanniocalcins as inhibitors of PAPP-A-mediated IGFBP cleavage (PMID 36718521). A 2026 study in the European Journal of Endocrinology examined the IGF–PAPP-A–stanniocalcin axis in men and women in the context of androgenic anabolic steroid use, extending measurement of the axis into a human observational setting (PMID 41715938). The 2026 Endocrine Reviews synthesis likewise linked stanniocalcin 1 to IGF signalling alongside calcium handling and tumour immunity (PMID 42446003).
Inflammation, injury and fibrosis models
Reported roles are context-dependent and not uniformly protective or harmful. In a 2024 Advanced Science paper, researchers reported that stanniocalcin-1 promoted PARP1-dependent cell death through JNK activation in models of colitis (PMID 38088577). A 2025 study reported that astrocyte-derived stanniocalcin-1 contributed to epileptogenesis through NF-κB-dependent neuroinflammation (PMID 41017753). By contrast, a 2022 report in the International Journal of Molecular Medicine described stanniocalcin-1 suppressing TGF-β-induced mitochondrial dysfunction and cellular fibrosis in human renal proximal tubular cells (PMID 35730604). Read together, the study designs suggest that direction of effect depended heavily on tissue and model.
Oncology research
Much of the volume of stanniocalcin literature sits in cancer biology. A 2022 review in the Journal of Hepatocellular Carcinoma examined the oncogenic and diagnostic potential of stanniocalcin 2 in hepatocellular carcinoma (PMID 35300206). In nasopharyngeal carcinoma models, researchers reported that stanniocalcin-2 promoted epithelial–mesenchymal transition and glycolysis via ITGB2/FAK/SOX6 signalling (PMID 33797657). A 2019 analysis in Current Medical Science examined stanniocalcin 2 expression in breast cancer tissue and its clinical significance (PMID 31845230), while a 2024 preprint reported that stanniocalcin 2 helped cancer cells adapt to nutrient insufficiency by alleviating oxidative stress (PMID 38464261).
For STC1, a 2024 Oncology Reports study reported that microRNA-606 inhibited growth and metastasis of triple-negative breast cancer cells by targeting stanniocalcin 1 (PMID 37975233), and a 2020 Nagoya Journal of Medical Science paper profiled stanniocalcin-1 mRNA expression across soft-tissue tumours (PMID 32273636).
Quick reference
| Term | What it refers to | Example of reported research context |
|---|---|---|
| Stanniocalcin (general) | Secreted glycoprotein hormone family; calcium/phosphate biology in its original description | Reviewed in relation to calcium homeostasis, IGF signalling and cancer immunity (PMID 42446003) |
| STC1 | Stanniocalcin-1; the closer mammalian homologue of the fish hormone | Reported to suppress TGF-β-induced fibrosis in human renal proximal tubular cells (PMID 35730604) |
| STC2 | Stanniocalcin-2; paralogue studied heavily in tumour datasets | Reported to promote EMT and glycolysis in nasopharyngeal carcinoma models (PMID 33797657) |
| STC–PAPP-A–IGFBP–IGF axis | Local control system for IGF bioavailability | Described as an integrated axis in a 2023 endocrinology review (PMID 36718521) |
Safety and Adverse Events: What Studies Report
The verified literature summarised here consists of reviews, expression analyses, cell-culture experiments and animal models; none of it described administering stanniocalcin to humans as a therapeutic agent, and so no human tolerability or adverse-event profile can be drawn from it. What researchers did report were biological consequences of stanniocalcin activity in disease models — for example, that stanniocalcin-1 promoted PARP1-dependent cell death via JNK activation in colitis (PMID 38088577) and that astrocyte-derived stanniocalcin-1 contributed to epileptogenesis through NF-κB-dependent neuroinflammation (PMID 41017753). Those are mechanistic findings in models, not safety data about a product.
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appCommon Points of Confusion
- Stanniocalcin is not a short synthetic peptide. It is a full-length glycoprotein, and the literature above studies it as an endogenous molecule.
- STC1 and STC2 are distinct genes. Findings for one were not automatically reported for the other; the 2019 breast cancer analysis, for instance, examined STC2 specifically (PMID 31845230).
- Direction of effect varied by tissue. Reported roles ranged from anti-fibrotic in renal tubular cells (PMID 35730604) to pro-death in colitis models (PMID 38088577).
- Biomarker ≠ treatment. Work such as the hepatocellular carcinoma review framed STC2 as having diagnostic as well as oncogenic interest (PMID 35300206).
This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, laboratory result or medication. It summarises what published research reported and does not describe any use of any substance.
References
- Stanniocalcin 1 at the nexus of calcium homeostasis, IGF signaling, and cancer immunity (Endocrine Reviews, 2026)
- The Stanniocalcin-PAPP-A-IGFBP-IGF Axis (The Journal of Clinical Endocrinology and Metabolism, 2023)
- IGF-PAPP-A-stanniocalcin axis and androgenic anabolic steroid use in men and women (European Journal of Endocrinology, 2026)
- Stanniocalcin-1 Promotes PARP1-Dependent Cell Death via JNK Activation in Colitis (Advanced Science, 2024)
- Astrocyte-derived stanniocalcin-1 orchestrates epileptogenesis through NF-κB-dependent neuroinflammation (Cell Cycle, 2025)
- Stanniocalcin-1 suppresses TGF-β-induced mitochondrial dysfunction and cellular fibrosis in human renal proximal tubular cells (International Journal of Molecular Medicine, 2022)
- The Oncogenic and Diagnostic Potential of Stanniocalcin 2 in Hepatocellular Carcinoma (Journal of Hepatocellular Carcinoma, 2022)
- Stanniocalcin-2 promotes cell EMT and glycolysis via activating ITGB2/FAK/SOX6 signaling pathway in nasopharyngeal carcinoma (Cell Biology and Toxicology, 2022)
- Expression of Stanniocalcin 2 in Breast Cancer and Its Clinical Significance (Current Medical Science, 2019)
- Stanniocalcin 2 governs cancer cell adaptation to nutrient insufficiency through alleviation of oxidative stress (Research Square, 2024)
- MicroRNA-606 inhibits the growth and metastasis of triple-negative breast cancer by targeting Stanniocalcin 1 (Oncology Reports, 2024)
- Stanniocalcin-1 mRNA expression in soft-tissue tumors (Nagoya Journal of Medical Science, 2020)
Frequently asked questions
What is stanniocalcin in one sentence?▾
Stanniocalcin is a secreted glycoprotein hormone, present in mammals as STC1 and STC2, originally identified in bony fish as a regulator of calcium and phosphate handling. A 2026 Endocrine Reviews synthesis described stanniocalcin 1 in relation to calcium homeostasis, IGF signalling and cancer immunity (PMID 42446003). It is an endogenous signalling protein studied in laboratories, not a dosing compound.
How does stanniocalcin relate to IGF signalling?▾
A 2023 review in the Journal of Clinical Endocrinology and Metabolism described the stanniocalcin–PAPP-A–IGFBP–IGF axis, in which the stanniocalcins inhibit PAPP-A, the protease that cleaves IGF-binding proteins and releases IGF for receptor binding (PMID 36718521). A 2026 European Journal of Endocrinology study measured this axis in men and women in the context of androgenic anabolic steroid use (PMID 41715938).
What is the difference between STC1 and STC2?▾
They are separate but related genes. Research on STC1 has included renal fibrosis models, where the study reported suppression of TGF-β-induced mitochondrial dysfunction (PMID 35730604), and soft-tissue tumour expression profiling (PMID 32273636). STC2 work has concentrated on tumour biology, including hepatocellular carcinoma (PMID 35300206) and breast cancer tissue expression (PMID 31845230).
Why does stanniocalcin appear so often in cancer papers?▾
Both homologues are frequently examined as biomarkers or candidate drivers. Researchers reported that stanniocalcin-2 promoted epithelial–mesenchymal transition and glycolysis in nasopharyngeal carcinoma models (PMID 33797657) and helped cancer cells adapt to nutrient insufficiency by alleviating oxidative stress (PMID 38464261). A separate study reported that microRNA-606 targeted stanniocalcin 1 in triple-negative breast cancer models (PMID 37975233).
Is stanniocalcin protective or harmful in tissue injury?▾
The published direction of effect depended on the model. One study reported stanniocalcin-1 suppressing TGF-β-induced fibrosis in human renal proximal tubular cells (PMID 35730604), while another reported that it promoted PARP1-dependent cell death via JNK activation in colitis (PMID 38088577). A 2025 report linked astrocyte-derived stanniocalcin-1 to epileptogenesis through NF-κB-dependent neuroinflammation (PMID 41017753).
Is stanniocalcin a research peptide in the usual sense?▾
Not in the sense of a short synthetic sequence. Stanniocalcin is a full-length secreted glycoprotein studied as an endogenous molecule through expression analysis, cell experiments and animal models, such as the soft-tissue tumour mRNA profiling reported in 2020 (PMID 32273636). The verified literature summarised here did not describe administering stanniocalcin to humans as a therapy.
Does the literature describe human dosing of stanniocalcin?▾
No. The papers cited on this page are reviews, tissue-expression analyses, cell-culture experiments and animal models rather than administration trials, so no human dose, schedule or tolerability profile can be drawn from them. Human measurement work, such as the 2026 study of the IGF–PAPP-A–stanniocalcin axis in steroid users, was observational (PMID 41715938). This information is educational only.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.